Abbott Neuromodulation's Jenn Wong discusses the TRANSCEND trial for depression, imaging tech advancing DBS and other ...

DBS for treatment-resistant depression has not been approved by the U.S Food and Drug Administration (FDA) and the safety and ... September 2022, Abbott received Breakthrough Device designation ...

DBS for treatment-resistant depression has not been approved by the U.S Food and Drug Administration (FDA) and the safety and effectiveness ... In September 2022, Abbott received Breakthrough Device ...

DBS surgery had the added benefit of programming adjustments to minimise stimulation-related complications. Permanent neurological complications were most commonly reported for RF thalamotomy.

Abbott’s pulse field ablation system competes with products from Medtronic and Boston Scientific, which also have large ...

Abbott said its Volt system is designed to improve upon what it sees as the limitations of first-generation PFA devices. Abbott has trailed medtech competitors in bringing a PFA device to market ...

Parkinson's disease patients and advocates are marking Friday as the start of a new era for treatment of the illness as a ...

The approval is supported by the clinical data that has shown the device’s effectiveness and safety in adaptive DBS delivery. Subjects in clinical trials experienced increased time with no ...

The initiative aims to reduce treatment costs and reliance on imported medical devices. The 1.5 Tesla MRI system has been developed by SAMEER, an autonomous R&D institution under the Ministry of ...

Abbott Laboratories' second-generation pulse field ablation device for atrial fibrillation has received European CE Mark approval earlier than expected, the North Chicago-based company said today.

Safe Mode, which is a pre-installed Android functionality, is used by users to solve the problems of their devices by disabling third-party applications from running on the smartphone. Indeed ...